105 results
IP Health Blog
FDA Guidance on Quality Considerations for Clinical Research Involving Cannabis and Cannabis-Derived Compounds FDA Guidance on Quality Considerations for Clinical Research Involving Cannabis and Cannabis-Derived Compounds
February 24, 2023
IP Health Blog
FDA Draft Guidance on Evaluation of Therapeutic Equivalence FDA Draft Guidance on Evaluation of Therapeutic Equivalence
August 4, 2022
IP Health Blog
Final FDA Guidance on Safety Considerations for Medication Container Labels and Carton Labeling Final FDA Guidance on Safety Considerations for Medication Container Labels and Carton Labeling
June 10, 2022
IP Health Blog
Considerations for Protecting Trade Secrets in FDA Correspondence Considerations for Protecting Trade Secrets in FDA Correspondence
April 12, 2022
IP Health Blog
FDA Final Guidance on Enhancing the Diversity of Clinical Trial Populations FDA Final Guidance on Enhancing the Diversity of Clinical Trial Populations
November 19, 2020
IP Health Blog
FDA Final Guidance on Amendments and Requests for Final Approval to Tentatively Approved ANDAs FDA Final Guidance on Amendments and Requests for Final Approval to Tentatively Approved ANDAs
November 3, 2020
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.